OverviewSuggest Edit

Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. It operates in three core business units: Specialty Care, Vaccines, and General Medicines. The Specialty Care business unit focuses on rare diseases, multiple sclerosis, oncology, immunology, and rare blood disorders. The Vaccines business unit primarily operates through Sanofi Pasteur, a key supplier of life-saving vaccines in both developed and emerging markets. The General Medicines business unit offers treatments for diabetes, cardiovascular, as well as established products. The company also comprises Consumer Healthcare (CHC), a standalone business unit with integrated research, development, manufacturing, support, and information technology capabilities.

TypePublic
Founded2004
HQParis, FR
Websitesanofi.com
Employee Ratings3.3
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)100,409(-3%)
Job Openings449
Revenue (FY, 2020)€36 B
Share Price (Jun 2021)€88.9
Cybersecurity ratingBMore

Key People/Management at Sanofi

Paul Hudson

Paul Hudson

Chief Executive Officer & Director
Serge Weinberg

Serge Weinberg

Chairman of the Board of Directors
Olivier Charmeil

Olivier Charmeil

Executive Vice President, General Medicines
Natalie Bickford

Natalie Bickford

Executive Vice President, Chief People Officer
Karen Linehan

Karen Linehan

Executive Vice President, Legal Affairs and General Counsel
Philippe Luscan

Philippe Luscan

Executive Vice President, Global Industrial Affairs
Show more

Sanofi Office Locations

Sanofi has offices in Paris, Ambarès-et-Lagrave, Amilly, Antony and in 108 other locations
Paris, FR (HQ)
54, rue La Boétie
Ambarès-et-Lagrave, FR
1 Rue de la Vierge
Amilly, FR
196 Rue du Maréchal Juin
Amilly, FR
748 Rue du Maréchal Juin
Antony, FR
20 Avenue Raymond Aron
Chilly-Mazarin, FR
1 Avenue Pierre Brossolette
Show all (120)

Sanofi Financials and Metrics

Sanofi Revenue

Embed Graph
View revenue for all periods
Sanofi's revenue was reported to be €36.04 b in FY, 2020 which is a 0.2% decrease from the previous period.
EUR

Revenue (FY, 2020)

36.0b

Revenue growth (FY, 2019 - FY, 2020), %

(0.2%)

Gross profit (FY, 2020)

25.2b

Gross profit margin (FY, 2020), %

70%

Net income (FY, 2020)

12.4b

EBIT (FY, 2020)

14.1b

Market capitalization (11-Jun-2021)

111.0b

Closing stock price (11-Jun-2021)

88.9

Cash (31-Dec-2020)

13.9b

EV

120.8b
Sanofi's current market capitalization is €111 b.
Annual
EURFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

35.1b34.5b36.1b36.0b

Revenue growth, %

(2%)5%0%

Cost of goods sold

11.6b11.4b12.0b12.2b

Gross profit

24.6b24.2b25.7b25.2b
Half Year
EURH1, 2018H1, 2019H1, 2020

Revenue

16.1b17.0b17.2b

Cost of goods sold

5.3b5.4b5.5b

Gross profit

11.3b12.3b12.2b

Gross profit Margin, %

71%72%71%
Annual
EURFY, 2017FY, 2018FY, 2019FY, 2020

Cash

10.3b6.9b9.4b13.9b

Accounts Receivable

7.2b7.3b7.9b7.5b

Prepaid Expenses

336.0m469.0m493.0m525.0m

Inventories

6.8b7.5b8.0b8.4b
Half Year
EURH1, 2018H1, 2019H1, 2020

Cash

7.5b6.7b16.0b

Accounts Receivable

6.6b7.2b7.2b

Inventories

7.4b8.4b8.9b

Current Assets

23.9b25.3b34.8b
Annual
EURFY, 2017FY, 2018FY, 2019FY, 2020

Depreciation and Amortization

3.7b4.3b7.5b3.7b

Inventories

(145.0m)(701.0m)(547.0m)(593.0m)

Accounts Payable

577.0m270.0m169.0m86.0m

Cash From Operating Activities

7.4b5.5b7.7b7.4b
Half Year
EURH1, 2018H1, 2019H1, 2020

Depreciation and Amortization

1.8b3.8b2.0b

Inventories

(627.0m)(934.0m)(1.0b)

Accounts Payable

(219.0m)(49.0m)(325.0m)

Cash From Operating Activities

1.8b3.2b3.9b
EURFY, 2017

EV/EBIT

18.5 x

EV/CFO

14.6 x

Revenue/Employee

329.0k

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.7 x

P/E Ratio

12.3
Show all financial metrics

Sanofi Operating Metrics

FY, 2018FY, 2019

Production Sites

7573

R&D Centers

2020

Suppliers

86 k68 k

Projects in R&D Pipeline

8191
Show all operating metrics

Sanofi Acquisitions / Subsidiaries

Company NameDateDeal Size
Kiadis PharmaNovember 02, 2020€308 m
Principia BioPharmaAugust 17, 2020$3.4 b
SynthorxDecember 09, 2019$2.5 m
AblynxJanuary 29, 2018$4.8 b
BioverativJanuary 22, 2018$11.6 b
Aventis S.A.August 30, 2004
Ablynx N.V.
Allston Landing Limited Partnership
A. Nattermann & Cie. GmbH
AO Sanofi Russia
Show more

Sanofi Revenue Breakdown

Embed Graph

Sanofi revenue breakdown by business segment: 16.6% from Vaccines, 71.2% from Pharmaceuticals and 12.2% from Consumer Healthcare

Sanofi revenue breakdown by geographic segment: 39.0% from North America, 35.6% from Other Countries and 25.4% from Europe

Human Capital Metrics

Embed Graph
Show all human capital metrics

Sanofi Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Sanofi Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Sanofi Online and Social Media Presence

Embed Graph

Sanofi Company Culture

  • Overall Culture

    B

    71/100

  • CEO Rating

    B

    70/100

  • Compensation

    B+

    75/100

  • Diversity

    B+

    73/100

Learn more on Comparably

Sanofi News and Updates

Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

White House to allow AstraZeneca, Novavax, Sanofi to distribute COVID-19 shots how they see fit

The White House said Thursday that it removed a requirement that is part of the Defense Production Act that gives the U.S. preferential orders for the COVID-19 vaccines developed by AstraZeneca , Novavax Inc. , and Sanofi . None of these shots have been authorized in the U.S., but the change allows …

Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects

Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects

Worldwide Active Pharmaceutical Ingredients (API) Industry to 2026 - Key Players Include Pfizer, Novartis and Sanofi Among Others

Dublin, June 02, 2021 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients (API) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global active pharmaceutical ingredients (API) market reac…

Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States

BRIDGEWATER, N.J. and KENILWORTH, N.J., June 1, 2021 /PRNewswire/ -- Vaxelis™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine), developed as part of a partnership between Sanofi Pasteur, the global vaccines...

New Covid-19 Vaccine Will Be Produced This Year As Sanofi, GSK Launch Phase 3 Trial

One part of the trial will test the vaccine against the South African variant of the virus.
Show more

Sanofi Frequently Asked Questions

  • When was Sanofi founded?

    Sanofi was founded in 2004.

  • Who are Sanofi key executives?

    Sanofi's key executives are Paul Hudson, Serge Weinberg and Olivier Charmeil.

  • How many employees does Sanofi have?

    Sanofi has 100,409 employees.

  • What is Sanofi revenue?

    Latest Sanofi annual revenue is €36 b.

  • What is Sanofi revenue per employee?

    Latest Sanofi revenue per employee is €358.9 k.

  • Who are Sanofi competitors?

    Competitors of Sanofi include Viatris, AstraZeneca and Eli Lilly.

  • Where is Sanofi headquarters?

    Sanofi headquarters is located at 54, rue La Boétie, Paris.

  • Where are Sanofi offices?

    Sanofi has offices in Paris, Ambarès-et-Lagrave, Amilly, Antony and in 108 other locations.

  • How many offices does Sanofi have?

    Sanofi has 120 offices.